Relacorilant Demonstrates Sustained Efficacy in Hypertension Control for Patients with Cushing’s Syndrome: Results from the Phase 3 GRACE Study
The Phase 3 GRACE trial demonstrates that relacorilant, a selective glucocorticoid receptor modulator, significantly maintains hypertension control in patients with Cushing’s syndrome without the safety concerns associated with non-selective antagonists, such as adrenal insufficiency or hypokalemia.